










¬†







Hedge Funds: 
  Cormorant Asset Management, LLC











Hedge Funds
Public Info on a Private Industry




Funds
Books
Contact





Cormorant Asset Management, LLC





Read About Hedge Funds








Key Facts

HeadquartersBoston, MA
Employees7
AUM$1.8 billion
AUM as ofMay 12, 2016
Clients6











Overview
  Cormorant Asset Management, LLC is a hedge fund based in Boston, MA.
   It was founded in 04/2014.
  They hold $1.8 billion in assets under management as of May 12, 2016.
  Read their Plain English Brochure.

Sub Funds and Performance


NameAUM (bn)
Type
Min Investment
Num Clients
Internal $ %
Fund of Funds $ %
Prime Brokers


Cormorant Global Healthcare Master Fund, LP 1.764
hedge fund
1,000,000
83
13.0
60.0
Goldman, Merrill, Morgan Stanley


Cormorant Private Healthcare Fund I, LP 0.074
private equity fund
5,000,000
14
44.0

Goldman




Key People


NameTitlePositionOwnership


 Bihua ChenManaging Member & Chief Executive Officer
Owner or Officer> 75%


 Nebojsa ObradovicChief Compliance Officer
Owner or OfficerNone


 Edward ScollinsMember, Chief Financial Officer & Chief Operating Officer
Owner or OfficerNone












    Copyright ¬© 2016 Track Hedge Funds.  
    
      
      Login








Cormorant Global Healthcare Fund, LP: Private Company Information - Bloomberg









































  





















































































July 28, 2017 6:20 AM ET
Capital Markets

Company Overview of Cormorant Global Healthcare Fund, LP



Snapshot¬†People




Company Overview
Cormorant Global Healthcare Fund, LP is a hedge fund launched and managed by Cormorant Asset Management, LLC. The fund invests in the public equity markets. It primarily invests in stocks of companies operating in the healthcare sector. The fund employs long/short strategy to make its investments. Cormorant Global Healthcare Fund, LP was formed on May 1, 2013 and is domiciled in United States.


200 Clarendon Street52nd FloorBoston, MA¬†02116United States



Phone: 857-702-0370

Fax: 617-507-5905








Key Executives for Cormorant Global Healthcare Fund, LP




Ms. Bihua Chen


      	Portfolio Manager
      





Compensation as of Fiscal Year 2017. 



Similar Private Companies By Industry



Company Name
Region



 @Visory LLC United States 1 Road Partners LLC United States 11T Partners, LLC United States 123Jump.com, Inc. United States 1509225 Ontario, Inc. United States




Recent Private Companies Transactions



TypeDate
Target



No transactions available in the past 12 months.




Request Profile Update

















¬†












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States The Advertising Council, Inc. United States Bertelsmann AG Europe Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
¬†|¬†
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Cormorant Global Healthcare Fund, LP, please visit --.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on‚Ä¶ We‚Äôre sorry but this didn‚Äôt work.                  You can‚Äôt turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let‚Äôs get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser‚Äôs Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the ‚ÄúPersonalized ads in this browser‚Äù tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft‚Äôs privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show ‚Äúgeneric‚Äù ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show ‚Äúgeneric‚Äù ads, click Off.         If you choose ‚Äúgeneric‚Äù ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You‚Äôll still see ads, but they won‚Äôt be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
¬© 2017 Microsoft












Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on‚Ä¶ We‚Äôre sorry but this didn‚Äôt work.                  You can‚Äôt turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let‚Äôs get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser‚Äôs Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the ‚ÄúPersonalized ads in this browser‚Äù tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft‚Äôs privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show ‚Äúgeneric‚Äù ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show ‚Äúgeneric‚Äù ads, click Off.         If you choose ‚Äúgeneric‚Äù ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You‚Äôll still see ads, but they won‚Äôt be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
¬© 2017 Microsoft









Ôªø







Why Cormorant Global Healthcare Master Fund Just Disclosed Huge New Sorrento Therapeutics Inc Stake ‚Äì Octafinance



















































 








Friday, 28 July 2017

























 

Menu



Featured News


						2 years ago - Alphabet Inc (NASDAQ:GOOGL) Tests Its Ad Technology On Billboards To Cushion Itself Against Ad Blocks


						2 years ago - China Margin Debt Hits 8-Week High, Japan Pumps‚Äôn‚ÄôDumps As Kyle Bass Fears Looming EM Banking Crisis


						2 years ago - Marc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and Gold


						2 years ago - Carl Icahn Criticizes the Fed. Feels Bad For Investors Buying Junk Bonds


						2 years ago - John Burbank: European QE Can‚Äôt Save The Markets Same As the U.S. Quantitative Easing. Everything Will Be Liquidated










Why Cormorant Global Healthcare Master Fund Just Disclosed Huge New Sorrento Therapeutics Inc Stake


05/26/2015  by OctaStaff 
			in SEC 13G & 13D Filings 












Share with your friendsYour NameYour EmailRecipient EmailEnter a MessageI read this article and found it very interesting, thought it might be interesting for you. The article is called Why Cormorant Global Healthcare Master Fund Just Disclosed Huge New Sorrento Therapeutics Inc Stake and is was published by Octafinance.com at http://www.octafinance.com/why-cormorant-global-healthcare-master-fund-just-disclosed-huge-new-sorrento-therapeutics-inc-stake/65649/.CaptchaSubmitCormorant Global Healthcare Master Fund New Position in Sorrento Therapeutics Inc (NASDAQ:SRNE)
Cormorant Global Healthcare Master Fund has filled a SC 13G form regarding Sorrento Therapeutics, Inc  2.00 -0.05 -2.44%. Filing Link: 
Sorrento Therapeutics, Inc Hedge Funds Ownership
Latest SEC filings show 54 hedge funds and institutional investors own Sorrento Therapeutics, Inc. The institutional ownership of the company in Q1 2015 is high, at 29.45% of the shares outstanding. They increased by 1598264 the total shares they hold. As of that quarter these institutional investors owned 10679039 shares. A total of 20 funds opened new positions in Sorrento Therapeutics, Inc and 16 increased their holdings. There were 4 funds that closed their positions and 13 that reduced them.
2 investors have the firm in their Top 10. Some of these are: Venbio Select Advisor Llc, Cormorant Asset Management Llc..
 Belmont Global Advisors Inc is the most positive institutional investor on Sorrento Therapeutics, Inc, with ownership of 50000 shares as of Q1 2015 for 0.59% of the fund‚Äôs portfolio.  Venbio Select Advisor Llc is another positive player owning 2214043 shares of the company or 9.82% of their stocks portfolio. MA Cormorant Asset Management Llc have 2.95% of their stock portfolio invested in the stock for 1652912. Further, Aisling Capital Llc disclosed it had purchased a stake worth 2.67% of the fund‚Äôs stock portfolio in the company. The NJ Healthcare Value Capital Llc was also a notable investor in the firm, owning 125000 shares. Sorrento Therapeutics, Inc is 1.57% of the fund‚Äôs stock portfolio.
Company Profile
Sorrento Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of drug therapeutics. The Company‚Äôs primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for other indications, including immunology and infectious diseases. Its pipeline consists of lead oncology product Cynviloq, a micellar paclitaxel formulation, resiniferatoxin, a non-opiate, ultra potent and selective agonist of the transient receptor potential vanilloid-1 receptor for intractable pain in end-stage disease, as well as fully human therapeutic antibodies derived from its G-MAB library platform and antibody drug conjugates, and recombinant intravenous immunoglobulin. The Company‚Äôs wholly owned subsidiaries include IgDraSol, Inc., Sherrington Pharmaceuticals, Inc., Concortis Biosystems, and Sorrento Therapeutics, Inc. Hong Kong Limited.

Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake‚Äôs size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other ‚Äúchange of control‚Äù events, are not permitted by 13G filers.
Cormorant Global Healthcare Master Fund

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.







 



Agtc Advisors Fund Lp Just Bought Bg Medicine Inc Stake Polaris Venture Partners Iv Lp Just decreased Acceleron Pharma Inc‚Äôs Stake 



 





Free Email Newsletter
    Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:







Hedge Fund NewsTop 10 CITADEL ADVISORS 13F Holdings in Q3 2015DF DENT & CO INC Just Released Its Q3 2015 Stock PositionsMAVERICK CAPITAL Top 10 Holdings in Q3 2015Analyzing Ken Griffins CITADEL ADVISORS Stock Holdings in Q3 2015LONE PINE CAPITAL Top 10 13F Positions in Q3 2015Guru NewsFelix Zulauf Sees a Stock Market Correction Coming. This Rally S&P 500 (INDEXSP:.INX) Will Be Short-LivedMarc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and GoldJim Grant: The Next Thing Might Be Helicopter Money. What to Buy and Where He Sees Investment OpportunitiesKyle Bass Bearish on Emerging Markets for at least 2 More Years. Looking to Short CurrenciesDavid Tepper Gets Defensive. Is it Time to Get Out of The Stock Market?


Macro NewsChina Margin Debt Hits 8-Week High, Japan Pumps‚Äôn‚ÄôDumps As Kyle Bass Fears Looming EM Banking CrisisAre US ‚Äì Russian Relations A Zero-Sum Game?US and Russia have launched direct talks on the conflict in SyriaYuan Drops as PBOC Cuts Reference Rate by Most Since DevaluationCould the market crash like 1987?‚Äîput volume spike argues low is nearCTAs NewsRed Rock Just Published Report About The Trend Following Landscape & How CTAs‚Äô Performance Must Be AnalyzedHow to Implement Dual Momentum for non-US InvestorsDo Commodity Trading Advisors (CTAs) Really Provide Crisis Alpha, Equity Hedge and Are Long Volatility?






















CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
                    

‚Ä¢   BOSTON, MA
                      
How do I update this listing?




                                             Cormorant Global Healthcare Master Fund is based out of Boston.    WhaleWisdom has at least 25 13D/G filings in our database for Cormorant Global Healthcare Master Fund.
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




√ó
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




cormorant global healthcare master fund, lp


200 CLARENDON STREET

BOSTON
MA
                                                      ¬†¬†
                                                    02116


              Business Phone:
              617-848-3429







Recent SEC Filings




SC 13G/A filed on 02/03/2017
4 filed on 12/14/2016
4 filed on 12/09/2016
4 filed on 12/06/2016
4 filed on 12/01/2016
4 filed on 11/23/2016
4 filed on 11/14/2016
4 filed on 11/07/2016
3 filed on 11/07/2016
3 filed on 06/13/2016











Current 13D/G Holdings


Stock
Sector
Shares Held
Market Value
Rank
Source
Source Date





ARDELYX INC (ARDX)


      HEALTH CARE
    

      1,481,075
    

      26,837,079.00
    

      1
    

      13G
    

      2015-12-31
    



Omeros Corp (OMER)


      HEALTH CARE
    

      1,960,000
    

      25,205,600.00
    

      2
    

      13G
    

      2015-09-22
    



Quotient Limited (QTNT)


      HEALTH CARE
    

      1,519,100
    

      24,305,600.00
    

      3
    

      13G
    

      2015-12-31
    



Sorrento Therapeutics, Inc. (SRNE)


      INFORMATION TECHNOLOGY
    

      2,095,334
    

      18,250,359.14
    

      4
    

      13G
    

      2015-12-31
    



Proteostasis Therapeutics Inc (PTI)


      HEALTH CARE
    

      1,725,460
    

      9,921,395.00
    

      5
    

      13G
    

      2016-02-16
    



RECRO PHARMA INC (REPH)


      HEALTH CARE
    

      780,000
    

      7,020,000.00
    

      6
    

      13G
    

      2015-12-31
    



VITAE PHARMACEUT (VTAE)


      HEALTH CARE
    

      1,435,000
    

      6,844,950.00
    

      7
    

      13G
    

      2016-03-11
    



Intec Pharma Ltd (NTEC)


      HEALTH CARE
    

      800,000
    

      4,800,000.00
    

      8
    

      13G
    

      2015-08-04
    



Zynerba Pharmaceuticals Inc (ZYNE)


      HEALTH CARE
    

      475,035
    

      2,826,458.25
    

      9
    

      13G
    

      2016-02-23
    



APTOSE BIOSCIENC (APTO)


      HEALTH CARE
    

      1,081,867
    

      2,737,123.51
    

      10
    

      13G
    

      2015-12-31
    



GenVec, Inc. (GNVC)


      HEALTH CARE
    

      1,176,235
    

      2,187,797.10
    

      11
    

      13G
    

      2015-12-31
    











Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free

















Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenixHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreTry Yahoo Finance on Firefox¬†¬ªYahooSearchSearchSign inU.S. Markets open in 3 hrs 10 minsS&P Futures2,462.75-9.25 (-0.37%)Dow Futures21,701.00-42.00 (-0.19%)Nasdaq Futures5,851.25-58.25 (-0.99%)Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenixGlobeNewswire‚Ä¢July 20, 2016ReblogShareTweetShareREGULATED INFORMATIONPRESS RELEASECormorant Asset Management, LLC notifies 5.81% shareholding in TiGenixLeuven (Belgium) - July 20, 2016, 7:00h CEST - TiGenix NV (Euronext Brussels: TIG) publishes today the transparency notification pursuant to Article¬†14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.Summary of the notificationOn July 19, 2016, TiGenix NV received a transparency notification from Cormorant Asset Management, LLC, following the acquisition of shares on March 14, 2016 by two entities controlled by it (i.e., Cormorant Global Healthcare Master Fund, LP and CRMA SPV, LP) after which Cormorant Asset Management, LLC has the discretionary power to exercise 11,756,894 voting rights in TiGenix NV (5.81% of the voting rights). As a result the 5% threshold was crossed.Content of the notification by Cormorant Asset Management, LLCDate of the notification: July 19, 2016.Reason of the notification: acquisition of shares.Person subject to the notification requirement: Cormorant Asset Management, LLC, who is a person that notifies alone.Date on which the threshold was crossed: March 14, 2016.Threshold that was crossed: 5%.Denominator: 202,304,587.Details of the notification: following the acquisition of shares, the number of voting rights was as follows: Cormorant Asset Management, LLC holds 11,756,894 voting rights in TiGenix NV (5.81% of voting rights). Chain of controlled undertakings through which the holdings are effectively held: Cormorant Asset Management, LLC is not a controlled entity. Cormorant Asset Management, LLC has received the discretionary power to exercise the voting rights of 11,756,894 TiGenix shares from the following two entities, which are both controlled by it: Cormorant Global Healthcare Master Fund, LP and CRMA SPV, LP.This press release and the above-mentioned transparency notifications can be consulted on our website: press release: http://www.tigenix.com/en/pages/11/2016;  notifications: http://www.tigenix.com/en/page/26/shareholders. For more information:TiGenix NVClaudia D`AugustaChief Financial OfficerT: +34 91 804 92 64 claudia.daugusta@tigenix.comAbout TiGenixTiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn`s disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic cardiac indication. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com.This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: TiGenix via GlobeNewswireHUG#2029536ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextSean Hannity responds to claim he ran up a $42,000 tab at Trump's hotel after flying in a 70-year-old lobster from MaineBusiness InsiderThis Will Be In Everyone's Household By 2020Banyan HillSponsoredMattis was on vacation when Trump tweeted transgender ban, and he was reportedly 'appalled' by itBusiness InsiderTrump‚Äôs unwitting legacy could be universal health coverageYahoo FinanceVirgin Atlantic founder Sir Richard Branson sells 31pc stake in airline for ¬£220m as part of new tie-up with Air France-KLMThe TelegraphZuckerberg Wife's Ambitious Secret Finally ExposedUNewz.MeSponsoredTwitter is only famous now because of President Trump: NYSE traderYahoo Finance VideoGDP ‚Äî What you need to know in markets on FridayYahoo FinanceRepublicans kill the border taxYahoo FinanceEngineer Finds Pattern; Makes Millions in StocksMoney MorningSponsoredAmazon wobble creates ripples across worldwide stock marketsReutersA PGA Tour pro explained what separates Jordan Spieth from fellow stars like Rory McIlroy and Dustin JohnsonBusiness InsiderVerizon Q2 Revenue Flat as Wireless Unit Sales Decline 1.9% Despite Subcriber ReboundVariety"Women Need To Carry This Device With Them"Siren SongSponsoredAmazon could be the first trillion dollar company: NYSE traderYahoo Finance VideoRolls-Royce Motor CEO: We‚Äôre not in the auto business. We‚Äôre in the luxury business.Yahoo FinanceTrump Is Acting Suspicious Because He ‚ÄòMay Be‚Äô Innocent, Fox News SaysBen: I always hire a slew of lawyers when I haven't done anything so it makes perfect sense. üòÇüòÇJoin the Conversation1 / 5585











Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix | Euronext




























Skip to Content
Skip to Navigation
 













Indices - index types - footer










	Companies listed on Euronext are indexed according to size, segments, sectors and per national market. It is not necessary to apply for inclusion in an index, just as a company cannot block its inclusion.


 
  

 
 



About Euronext



About us
Investisseurs
Actualit√©
Contact us
‰∏≠Êñá
 

 
 








 
 








Languages



EN
FR
NL
PT
 

 
 



Recherche










 Recherche cours


 Recherche site









 
 





Euronext


 






Lev√©e de capitaux
Acc√©der aux march√©s de capitaux
Financement par action
R√©aliser une √©mission obligataire
Autres op√©rations de financement
Proc√©dures d‚Äôadmissions, obligations de d√©claration, formulaires d‚Äôapplication 
Including: Application Forms, Listing Fees
International Listings
FastPath
SMEs
Family Business
Tech
Services pour les √©metteurs
Listing Sponsors
Ev√©nements
Corporate Actions
Assistance client√®le
Questions fr√©quentes
Issuer Directory
Introductions en bourse
Euronext
Euronext Growth‚Ñ¢
Euronext Access‚Ñ¢
Next Step
Trading & Produits
Equities
Fixed Income
Funds
ETFs
Warrants & Certificates
Indices
Equity Derivatives
Including: Stock Options, Stock Futures, Dividend Derivatives, Equity Index Derivatives, ETF Options
FX Derivatives
Commodities
Euronext Synapse
Euronext Block (MTF)
Euronext Expert Market
AtomX
Euronext Collateral Services
ETF One-Stop Shop
Trading Services
Market Status
Calendrier & Horaires
Fees & Charges
Market Quality
Membership
Connectivity
Service & Support
Donn√©es de march√©
Products By Type
Including: Corporate Actions, Historical Data, Index Data, Master Files, Real-Time, Reference Data
Products By Asset Type
Including: Bonds, Derivatives, ETPs, Equities
Derivatives
Documentation
Market Data News
Web Services
Euronext App
Technologie
Optiq
Market solutions for exchanges
Including: Exchange Data Publisher, Universal Trading Platform
Ressources
Calendars & Hours
Rules & Regulations
MiFID II
Reports & Statistics
Including: Statistics, Index Reports, Exchange Delivery Settlement Price (EDSP), Commodities Delivery Reports
IT Documentation
Equity Derivatives Newsletter
Commodities Newsletter
Events
Euronext Publications
Including: Notices, Info-Flashes, Corporate Actions
Listed Company Publications
Including: Company Press Releases, Annual Reports, Financial Calendars
 

 
 




 

 
 


 










Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix
View All Press Releases







        Libell√© soci√©t√©:
      

TIGENIX



        March√©:
      
Euronext



        ISIN:
      
BE0003864817



        Symbole:
      
TIG




RELEASE 20 JUL 2016 07:03 CET


Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix
REGULATED INFORMATIONPRESS RELEASE Cormorant Asset Management, LLC notifies 5.81% shareholding in TiGenix Leuven (Belgium) - July 20, 2016, 7:00h CEST - TiGenix NV (Euronext Brussels: TIG) publishes today the transparency notification pursuant to Article¬†14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions. Summary of the notification On July 19, 2016, TiGenix NV received a transparency notification from Cormorant Asset Management, LLC, following the acquisition of shares on March 14, 2016 by two entities controlled by it (i.e., Cormorant Global Healthcare Master Fund, LP and CRMA SPV, LP) after which Cormorant Asset Management, LLC has the discretionary power to exercise 11,756,894 voting rights in TiGenix NV (5.81% of the voting rights). As a result the 5% threshold was crossed. Content of the notification by Cormorant Asset Management, LLC Date of the notification: July 19, 2016. Reason of the notification: acquisition of shares. Person subject to the notification requirement: Cormorant Asset Management, LLC, who is a person that notifies alone. Date on which the threshold was crossed: March 14, 2016. Threshold that was crossed: 5%. Denominator: 202,304,587. Details of the notification: following the acquisition of shares, the number of voting rights was as follows:   Cormorant Asset Management, LLC holds 11,756,894 voting rights in TiGenix NV (5.81% of voting rights).   Chain of controlled undertakings through which the holdings are effectively held: Cormorant Asset Management, LLC is not a controlled entity. Cormorant Asset Management, LLC has received the discretionary power to exercise the voting rights of 11,756,894 TiGenix shares from the following two entities, which are both controlled by it: Cormorant Global Healthcare Master Fund, LP and CRMA SPV, LP. This press release and the above-mentioned transparency notifications can be consulted on our website:   press release: http://www.tigenix.com/en/pages/11/2016;    notifications: http://www.tigenix.com/en/page/26/shareholders.   For more information: TiGenix NVClaudia D`AugustaChief Financial OfficerT: +34 91 804 92 64 claudia.daugusta@tigenix.com About TiGenix TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn`s disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic cardiac indication. On July 4, 2016, we entered into a licensing agreement with Takeda, a large pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to commercialize Cx601 for complex perianal fistulas outside the United States. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com. HUG#2029538


      Source: TiGenix    
Fournisseur: Thomson Reuters ONE


 
 
 

 

 
 
 
 






EnterNext



Enternext.biz
Belgium
France
Introductions
Portugal
A propos d‚ÄôEnterNext
Enternext IPOs
 

 
 



Investors



Aex.nl
Beurs.be
Bourse.be
Bolsadelisboa.com.pt
Boursedeparis.fr
My Euronext
 

 
 



Solutions



Market data
Realtime data
Historical data
Corporate actions
Index data
Technology
Euronext Corporate Services
 

 
 



Resources



Ressources
IT-Documentation
Statistiques
R√©glementation
Cash notices
Derivatives notices
 

 
 



More...



Euronext.asia
Rohstoffe
 

 
 








Disclaimer Footer



¬© 2017 Euronext
Conditions d'utilisation
Privacy Policy
 

 
 









